Nikolaos Settas1, Rebecca Persky1, Fabio R Faucz1, Nicole Sheanon2, Antonis Voutetakis1, Maya Lodish1, Louise A Metherell3, Constantine A Stratakis1. 1. Section on Endocrinology and Genetics, Program on Developmental Endocrinology and Genetics & Pediatric Endocrinology Inter-Institute Training Program, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland. 2. Division of Pediatric Endocrinology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio. 3. Centre for Endocrinology, William Harvey Research Institute, Queen Mary University of London, Charterhouse Square, London, United Kingdom.
Abstract
CONTEXT: Multiple autosomal recessive genes have been etiologically linked to primary adrenal insufficiency (PAI). Recently, sphingosine-1-phosphate lyase 1 (SGPL1) gene mutations were recognized as a cause of steroid-resistant nephrotic syndrome type 14 (NPHS14), a sphingolipidosis with multisystemic manifestations, including PAI. OBJECTIVE: To check if SGPL1 mutations are involved in the pathogenesis of PAI in patients who do not exhibit nephrotic syndrome. METHODS: Sequencing of the SGPL1 gene in 21 patients with familial glucocorticoid disease or triple A syndrome. RESULTS: We identified two missense SGPL1 variants in four patients, two of whom were first cousins. We describe in detail the proband, a boy born to Saudi Arabian consanguineous parents with a homozygous c.665G>A, p.R222Q SGPL1 variant. The patient presented with hypoglycemia and seizures at age 2 years and was ultimately diagnosed with PAI (isolated glucocorticoid deficiency). Brain MRI showed abnormalities in the basal ganglia consistent with a degenerative process albeit the patient had no neurologic symptoms. CONCLUSIONS: New genetic causes of PAI continue to be identified. We suggest that screening for SGPL1 mutations should not be reserved only for patients with nephrotic syndrome but may also include patients with PAI who lack other clinical manifestations of NPHS14 because, in certain cases, kidney disease and accompanying features might develop. Timely diagnosis of this specific sphingolipidosis while the kidneys still function normally can lead to prompt initiation of therapy and improve outcome. Published by Oxford University Press on behalf of the Endocrine Society 2019.
CONTEXT: Multiple autosomal recessive genes have been etiologically linked to primary adrenal insufficiency (PAI). Recently, sphingosine-1-phosphate lyase 1 (SGPL1) gene mutations were recognized as a cause of steroid-resistant nephrotic syndrome type 14 (NPHS14), a sphingolipidosis with multisystemic manifestations, including PAI. OBJECTIVE: To check if SGPL1 mutations are involved in the pathogenesis of PAI in patients who do not exhibit nephrotic syndrome. METHODS: Sequencing of the SGPL1 gene in 21 patients with familial glucocorticoid disease or triple A syndrome. RESULTS: We identified two missense SGPL1 variants in four patients, two of whom were first cousins. We describe in detail the proband, a boy born to Saudi Arabian consanguineous parents with a homozygous c.665G>A, p.R222QSGPL1 variant. The patient presented with hypoglycemia and seizures at age 2 years and was ultimately diagnosed with PAI (isolated glucocorticoid deficiency). Brain MRI showed abnormalities in the basal ganglia consistent with a degenerative process albeit the patient had no neurologic symptoms. CONCLUSIONS: New genetic causes of PAI continue to be identified. We suggest that screening for SGPL1 mutations should not be reserved only for patients with nephrotic syndrome but may also include patients with PAI who lack other clinical manifestations of NPHS14 because, in certain cases, kidney disease and accompanying features might develop. Timely diagnosis of this specific sphingolipidosis while the kidneys still function normally can lead to prompt initiation of therapy and improve outcome. Published by Oxford University Press on behalf of the Endocrine Society 2019.
Authors: Susan R Schwab; João P Pereira; Mehrdad Matloubian; Ying Xu; Yong Huang; Jason G Cyster Journal: Science Date: 2005-09-09 Impact factor: 47.728
Authors: M Walterfang; M Fahey; P Desmond; A Wood; M L Seal; C Steward; C Adamson; C Kokkinos; M Fietz; D Velakoulis Journal: Neurology Date: 2010-05-19 Impact factor: 9.910
Authors: Eirini Meimaridou; Julia Kowalczyk; Leonardo Guasti; Claire R Hughes; Florian Wagner; Peter Frommolt; Peter Nürnberg; Nicholas P Mann; Ritwik Banerjee; H Nurcin Saka; J Paul Chapple; Peter J King; Adrian J L Clark; Louise A Metherell Journal: Nat Genet Date: 2012-05-27 Impact factor: 38.330
Authors: K W Martin; N Weaver; K Alhasan; E Gumus; B R Sullivan; M Zenker; F Hildebrandt; J D Saba Journal: AJNR Am J Neuroradiol Date: 2020-08-27 Impact factor: 3.825
Authors: Piming Zhao; Isaac D Liu; Jeffrey B Hodgin; Peter I Benke; Jeremy Selva; Federico Torta; Markus R Wenk; James A Endrizzi; Olivia West; Weixing Ou; Emily Tang; Denise Li-Meng Goh; Stacey Kiat-Hong Tay; Hui-Kim Yap; Alwin Loh; Nicole Weaver; Bonnie Sullivan; Austin Larson; Megan A Cooper; Khalid Alhasan; Abdullah A Alangari; Suha Salim; Evren Gumus; Karin Chen; Martin Zenker; Friedhelm Hildebrandt; Julie D Saba Journal: J Inherit Metab Dis Date: 2020-05-04 Impact factor: 4.982
Authors: Piming Zhao; Gizachew B Tassew; Joanna Y Lee; Babak Oskouian; Denise P Muñoz; Jeffrey B Hodgin; Gordon L Watson; Felicia Tang; Jen-Yeu Wang; Jinghui Luo; Yingbao Yang; Sarah King; Ronald M Krauss; Nancy Keller; Julie D Saba Journal: JCI Insight Date: 2021-04-22
Authors: Avinaash Maharaj; Demetria Theodorou; Indraneel Indi Banerjee; Louise A Metherell; Rathi Prasad; Dean Wallace Journal: Front Pediatr Date: 2020-04-08 Impact factor: 3.418